Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.68 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | IGF1R | P08069 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | PIM1 | P11309 | 6/20 | 0.57 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.57 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.56 |
| ▸ | CLK1 | P49759 | 2/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.56 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.56 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.56 |
| ▸ | CLK2 | P49760 | 1/20 | 0.56 |
| ▸ | CLK3 | P49761 | 1/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796814 | 1.00 | GSK3B (1.00) | GSK3BRAB9APIK3CAPIK3CGNPC1 | |
| SCHEMBL2882077 | 1.00 | GSK3B (1.00) | GSK3BRAB9APIK3CAPIK3CGNPC1 | |
| SCHEMBL29369746 | 0.91 | GSK3B (0.83) | GSK3BRAB9APIK3CAPIK3CGNPC1 | |
| SCHEMBL1249098 | 0.91 | GSK3B (0.83) | GSK3BRAB9APIK3CAPIK3CGNPC1 | |
| SCHEMBL2882197 | 0.91 | GSK3B (0.83) | GSK3BRAB9APIK3CAPIK3CGNPC1 | |
| SCHEMBL1249096 | 0.91 | GSK3B (0.83) | GSK3BRAB9APIK3CAPIK3CGNPC1 | |
| SCHEMBL30250232 | 0.87 | GSK3B (0.77) | GSK3BRAB9ANPC1PIM1DYRK1A | |
| SCHEMBL2884578 | 0.84 | DYRK1A (0.79) | GSK3BRAB9APIK3CAPIK3CGNPC1 | |
| SCHEMBL6795136 | 0.84 | DYRK1A (0.79) | GSK3BRAB9APIK3CAPIK3CGNPC1 | |
| SCHEMBL2884580 | 0.84 | DYRK1A (0.79) | GSK3BRAB9APIK3CAPIK3CGNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | claimed |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | MERCK SERONO SA (CH) | 2009-02-12 | — | — | US | claimed |
| EP-1807075-A2 | PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA | Applied Research Systems ARS Holding N.V. (AN) | 2007-07-18 | — | — | EP | claimed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | claimed |
| WO-2006040318-A2 | PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-04-20 | — | — | WO | claimed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | claimed |
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | LABORATOIRES SERONO S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | MERCK SERONO SA (CH) | 2009-02-12 | — | — | US | disclosed |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2008-12-11 | — | — | US | disclosed |
| EP-1807075-A2 | PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA | Applied Research Systems ARS Holding N.V. (AN) | 2007-07-18 | — | — | EP | disclosed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | disclosed |
| WO-2006040318-A2 | PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-04-20 | — | — | WO | disclosed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | disclosed |
| US-20040092561-A1 | Azolidinone-vinyl fused -benzene derivatives | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-05-13 | — | — | US | disclosed |
| WO-2000018746-A1 | THIAZOLIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | ZAP70, BRCA1, ZYX | GSK3B 2843/4885RAB9A 1515/4885PIK3CA 619/4885 |
| US-20040092561-A1 | Azolidinone-vinyl fused -benzene derivatives | BRCA1, ZAP70, ZYX | GSK3B 2800/4885RAB9A 1510/4885PIK3CA 410/4885 |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | PDPK1, PRKD3, PRKD1 | GSK3B 100/4885RAB9A 1524/4885PIK3CA 17/4885 |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | CATSPER1, PI4KB, MAN2B2 | GSK3B 1040/4885RAB9A 1737/4885PIK3CA 130/4885 |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | PDPK1, PIK3R4, MAP3K3 | GSK3B 126/4885RAB9A 1949/4885PIK3CA 29/4885 |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | BRCA1, ZAP70, F13B | GSK3B 3188/4885RAB9A 1504/4885PIK3CA 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.